WS #12213
The European Commission has approved the once-daily Wegovy pill, the first oral GLP-1 treatment for weight management in the EU, a landmark shift for obesity care. UnitedHealth reported better-than-expected Q2 results and raised its 2026 adjusted EPS guidance to $19.50-$20, with Medicare margins above 3%.
EU Approves Oral GLP-1 Pill (Wegovy)
The European Commission has approved the once-daily Wegovy pill, the first oral GLP-1 treatment for weight management in the EU, a landmark shift for obesity care.
UnitedHealth reported better-than-expected Q2 results and raised its 2026 adjusted EPS guidance to $19.50-$20, with Medicare margins above 3%.